Changes in Neutrophil-Lymphocyte or Platelet-Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis.
NLR
PLR
biomarker
clinical outcomes
idiopathic pulmonary fibrosis
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
01 Apr 2021
01 Apr 2021
Historique:
received:
06
01
2021
revised:
08
03
2021
accepted:
23
03
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Identification of prognostic and predictive biomarkers in idiopathic pulmonary fibrosis (IPF) could aid assessment of disease severity and prediction of progression and response to treatment. This analysis examined reference ranges for neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in IPF, and the relationship between NLR or PLR changes and clinical outcomes over 12 months. This post hoc analysis included patients with IPF from the Phase III, double-blind trials of pirfenidone, ASCEND (NCT01366209) and CAPACITY (NCT00287716 and NCT00287729). The relationship between change from baseline to Month 12 in NLR or PLR (divided into quartiles (Q1-Q4)) and outcomes (mortality, respiratory hospitalization, declines in lung function, exercise capacity and quality of life) was assessed. Estimated reference ranges at baseline for all patients analyzed (
Identifiants
pubmed: 33916077
pii: jcm10071427
doi: 10.3390/jcm10071427
pmc: PMC8037167
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Genentech, Inc.
ID : N/A
Organisme : F. Hoffmann-La Roche, Ltd.
ID : N/A
Références
J Immunol. 2017 Sep 1;199(5):1596-1605
pubmed: 28754682
Curr Stem Cell Rep. 2018;4(3):264-271
pubmed: 30148048
N Engl J Med. 2014 May 29;370(22):2083-92
pubmed: 24836312
Medicine (Baltimore). 2018 Jun;97(26):e11138
pubmed: 29952958
Am J Respir Cell Mol Biol. 2018 Aug;59(2):215-224
pubmed: 29444413
Respir Med. 2020 Aug - Sep;170:106068
pubmed: 32843183
Am J Respir Crit Care Med. 2013 Jan 15;187(2):180-8
pubmed: 23220917
N Engl J Med. 2014 May 29;370(22):2071-82
pubmed: 24836310
Front Med. 2014 Dec 22;1(56):
pubmed: 25580363
Lancet Respir Med. 2019 Jun;7(6):497-508
pubmed: 30935881
Lancet. 2011 May 21;377(9779):1760-9
pubmed: 21571362
Ann Transl Med. 2017 Jun;5(12):250
pubmed: 28706918
N Engl J Med. 2004 Jan 8;350(2):125-33
pubmed: 14711911
Int J Rheum Dis. 2015 Sep;18(7):731-5
pubmed: 25900081
Minerva Med. 2020 May 14;:
pubmed: 32407050
Lancet Respir Med. 2017 Dec;5(12):946-955
pubmed: 29150411
Lancet. 2009 Jul 18;374(9685):222-8
pubmed: 19570573
Biomed Res Int. 2018 Nov 11;2018:2703518
pubmed: 30534554
PLoS One. 2013 Jul 02;8(7):e67688
pubmed: 23844064
Oncotarget. 2017 Sep 27;8(51):88835-88844
pubmed: 29179480
J Leukoc Biol. 2015 Aug;98(2):143-52
pubmed: 25743626
PLoS One. 2014 Nov 06;9(11):e112361
pubmed: 25375150
N Engl J Med. 2018 May 10;378(19):1811-1823
pubmed: 29742380
Eur Respir Rev. 2018 Feb 7;27(147):
pubmed: 29436405
Respir Res. 2017 Sep 8;18(1):170
pubmed: 28886713
J Med Biochem. 2018 Jan 01;37(1):21-30
pubmed: 30581338
J Immunol. 2013 Sep 1;191(5):2089-95
pubmed: 23872052
Lancet Respir Med. 2018 Aug;6(8):615-626
pubmed: 30072107